Clinical Trials

The purpose of this study is to define the effectiveness and safety of Inebilizumab in reducing the level of disability in patients with NMDAR encephalitis as measured by modified Rankin score (mRS).

There are currently no medicinal products approved for the treatment of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, a rare disease. NMDAR encephalitis is a life‑threatening, antibody-mediated autoimmune disorder of the central nervous system. Standard of care includes high-dose corticosteroids AND either intravenous immunoglobulin (IVIg) OR plasmapheresis. However, as many as 47% of patients may fail to respond to initial treatment at 4 weeks, thus, there is a high unmet medical need for ...

The purose of this study is to assess the effectiveness and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

The purpose of the study is to assess the efficacy of rozanolixizumab as measured by seizure freedom, change in cognitive function, use of rescue medication, onset of seizure freedom and to assess safety and tolerability.

The purpose of this study is to examine paired serum and cerebrospinal fluid (CSF) samples from subjects with encephalitis, meningitis, and myelitis to investigate two (2) specific pathways suspected of playing a role in the host response to infection and/or inflammation.